Stock Research for AGEN

AGEN

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

AGEN Stock Chart & Research Data

The AGEN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AGEN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


AGEN Due diligence Resources & Stock Charts

The AGEN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View AGEN Detailed Price Forecast - CNN Money CNN View AGEN Detailed Summary - Google Finance
Yahoo View AGEN Detailed Summary - Yahoo! Finance Zacks View AGEN Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View AGEN Trends & Analysis - Trade-Ideas Barrons View AGEN Major Holders - Barrons
NASDAQ View AGEN Call Transcripts - NASDAQ Seeking View AGEN Breaking News & Analysis - Seeking Alpha
Spotlight View AGEN Annual Report - CompanySpotlight.com OTC Report View AGEN OTC Short Report - OTCShortReport.com
TradeKing View AGEN Fundamentals - TradeKing Charts View AGEN SEC Filings - Bar Chart
WSJ View Historical Prices for AGEN - The WSJ Morningstar View Performance/Total Return for AGEN - Morningstar
MarketWatch View the Analyst Estimates for AGEN - MarketWatch CNBC View the Earnings History for AGEN - CNBC
StockMarketWatch View the AGEN Earnings - StockMarketWatch MacroAxis View AGEN Buy or Sell Recommendations - MacroAxis
Bullish View the AGEN Bullish Patterns - American Bulls Short Pains View AGEN Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View AGEN Stock Mentions - StockTwits PennyStocks View AGEN Stock Mentions - PennyStockTweets
Twitter View AGEN Stock Mentions - Twitter Invest Hub View AGEN Investment Forum News - Investor Hub
Yahoo View AGEN Stock Mentions - Yahoo! Message Board Seeking Alpha View AGEN Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for AGEN - SECform4.com Insider Cow View Insider Transactions for AGEN - Insider Cow
CNBC View AGEN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for AGEN - OTC Markets
Yahoo View Insider Transactions for AGEN - Yahoo! Finance NASDAQ View Institutional Holdings for AGEN - NASDAQ


Stock Charts

FinViz View AGEN Stock Insight & Charts - FinViz.com StockCharts View AGEN Investment Charts - StockCharts.com
BarChart View AGEN Stock Overview & Charts - BarChart Trading View View AGEN User Generated Charts - Trading View




Latest Financial News for AGEN


Agenus Receives Milestone Payment from Incyte
Posted on Monday September 17, 2018

LEXINGTON, Mass., Sept. 17, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today receipt of a cash milestone from Incyte for the initiation of a Phase 1 clinical trial of INCAGN2385, an anti-LAG-3 antibody discovered by Agenus. Based on this milestone and under the terms of the agreement, Agenus received a $5 million payment and is eligible to receive up to an additional $505 million in potential development, regulatory and commercial milestones from Incyte. "This is the fourth antibody from our partnered programs that has advanced into clinical trials, once again proving our commitment to deliver on our existing partnerships," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus.


Implied Volatility Surging for Agenus (AGEN) Stock Options
Posted on Friday September 14, 2018

Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.


Analysts Still Bullish about BioLife Solutions
Posted on Thursday September 13, 2018

BioLife Solutions (BLFS) generated a net income of $1.05 million in the second quarter compared to a net loss of $768,212 in the second quarter of 2017. That translates to net income per share of $0.05 in the second quarter. Its net loss per share was $0.06 in the second quarter of 2017.


Why Agenus' Stock Perked Up in August
Posted on Friday September 07, 2018

Agenus broke out of its year-long funk last month, but this rally might be short-lived. Here's why.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.